- Home
- ARTV vs LUNG Comparison
ARTV vs LUNG Comparison
Compare ARTV & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARTV
- LUNG
- Stock Information
- Founded
- ARTV 2019
- LUNG 1995
- Country
- ARTV United States
- LUNG United States
- Employees
- ARTV N/A
- LUNG N/A
- Industry
- ARTV
- LUNG Industrial Specialties
- Sector
- ARTV
- LUNG Health Care
- Exchange
- ARTV NYSE
- LUNG Nasdaq
- Market Cap
- ARTV 232.8M
- LUNG 248.0M
- IPO Year
- ARTV 2024
- LUNG 2020
- Fundamental
- Price
- ARTV $11.79
- LUNG $8.65
- Analyst Decision
- ARTV Strong Buy
- LUNG Strong Buy
- Analyst Count
- ARTV 5
- LUNG 7
- Target Price
- ARTV $21.25
- LUNG $13.71
- AVG Volume (30 Days)
- ARTV 79.3K
- LUNG 280.2K
- Earning Date
- ARTV 08-29-2024
- LUNG 10-28-2024
- Dividend Yield
- ARTV N/A
- LUNG N/A
- EPS Growth
- ARTV N/A
- LUNG N/A
- EPS
- ARTV N/A
- LUNG N/A
- Revenue
- ARTV $29,256,000.00
- LUNG $76,583,000.00
- Revenue This Year
- ARTV N/A
- LUNG $22.73
- Revenue Next Year
- ARTV N/A
- LUNG $19.02
- P/E Ratio
- ARTV N/A
- LUNG N/A
- Revenue Growth
- ARTV 493.31
- LUNG 26.26
- 52 Week Low
- ARTV $9.71
- LUNG $5.46
- 52 Week High
- ARTV $16.00
- LUNG $14.84
- Technical
- Relative Strength Index (RSI)
- ARTV N/A
- LUNG 66.87
- Support Level
- ARTV N/A
- LUNG $8.01
- Resistance Level
- ARTV N/A
- LUNG $8.79
- Average True Range (ATR)
- ARTV 0.00
- LUNG 0.47
- MACD
- ARTV 0.00
- LUNG 0.12
- Stochastic Oscillator
- ARTV 0.00
- LUNG 88.31
About ARTV ARTIVA BIOTHERAPEUTICS INC
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.